signal/raiseTrack rounds
Series AHealthtech & bio · New York

Hone Health raises $228m in Series A extension and growth financing led by MarcyPen

Only $28m of the total is equity; the other $200m comes from General Catalyst's Customer Value Fund, which is repaid from revenue brought in by new customers, according to Dealroom.

s/rFunding deskNorth America · 2 min read

Hone Health, a New York online clinic that provides physician-led longevity and hormone care, said on 18 November 2026 that it had raised $228m in new financing.

The total is made up of $28m in equity, raised as an extension of the company's Series A round, and $200m in growth financing from General Catalyst's Customer Value Fund. MarcyPen Capital Partners led the round. Hone said MarcyPen had also led its earlier Series A, a role that had not been disclosed before. The company said its total equity funding is now $65m. It did not disclose a valuation.

Hone's earlier $33m Series A, announced in January 2025, valued the company at $313m, according to Dealroom.

“This funding will allow us to extend that vision across new therapeutic categories and start building toward our ultimate vision: a research platform to accelerate health outcomes.”Saad Alam, Co-Founder and CEO, Hone Health

What Hone Health does

Hone combines blood and biomarker testing, one-to-one consultations with physicians and ongoing treatment plans. It began by treating men with low testosterone, according to Dealroom, and now also offers menopause hormone therapy, weight management, peptides, thyroid, heart and sexual health care. Its physicians use the company's own AI clinical platform, called Longevity OS, to see each patient's data across specialties.

The company said it has treated more than 200,000 patients, administered 750,000 tests and processed 25 million health markers. Chief executive Saad Alam said Hone passed $100m in recurring revenue last year, according to The Investor Society. After its 2025 Series A, Hone added a cardiovascular programme that uses Prenuvo whole-body MRI and BodySpec DEXA scans.

Hone also used the announcement to launch Hone Black, a concierge membership that it said had run privately for a year for a small group of high-profile patients. It tests more than 1,600 health markers and assigns a dedicated team of physicians.

How the deal is structured

The $200m from General Catalyst is not equity. Dealroom reported that it pays for sales and marketing and is repaid from the revenue that new customers generate. The Investor Society reported that the fund takes a capped share of the value from customers it helps acquire, and quoted Alam as saying the arrangement has no recourse and no covenants that stop Hone raising other money. Dealroom said General Catalyst had used the same structure with preventive-health company Function and clinical AI company Heidi this year.

The equity extension included Pentland Ventures, Kinship Ventures, Hanwha, Gannet Capital, humbition, Comma Capital and ID Ventures. Kinship was co-founded by Gwyneth Paltrow and Moj Mahdara. David Grutman joined as an investor and adviser and brought in other individual backers, including Nick, Joe and Kevin Jonas and Kelly Rowland. MarcyPen was co-founded by Shawn "Jay-Z" Carter, according to Dealroom.

What the money is for

Hone said it would put the money into five areas: new physician-led programmes for metabolic health, inflammation and immunity; additional diagnostics such as full-body MRI, DEXA scans, coronary CT angiography and gut microbiome tests; AI tools that help physicians adjust care; a physician-supervised peptide programme where legally available; and infrastructure for clinical trials to study which treatments work best.

The Investor Society noted that pandemic-era rules allowing controlled substances such as testosterone to be prescribed by telehealth are due to expire on 31 December 2026, a date that matters for Hone's core hormone business.

Company website: honehealth.com